Posted by Michael Wonder on 14 Mar 2018
Valeant receives Health Canada approval of Siliq (brodalumab) for moderate-to-severe plaque psoriasis
14 March 2018 - Valeant Canada announced that Health Canada granted on 6 March the Notice of Compliance for Siliq (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis.
Siliq is indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Valeant expects to commence sales and marketing of Siliq in the Canada in the second half of 2018.
"An additional biologic has just received its approval: Siliq is the only biologic in the treatment of plaque psoriasis that has demonstrated a Psoriasis Area Severity Index (PASI) 100 as a primary endpoint," said Dr. Charles W. Lynde, MD, FRCPC, Diplomate American Boards, Dermatology, Associate Professor in the Department of Medicine at University of Toronto. "This IL-17A receptor antagonist decreases the pro-inflammatory cytokines IL-17resulting in rapid normalization of the psoriatic skin inflammation. Our moderate-to-severe plaque type psoriasis patients will benefit from this new drug being now on the market."
